Mark Eichenbaum, MD
Geriatric Medicine · Saint Petersburg, FLNPI 1871764977
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations.
Across 111 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$340
- Novartis$309
- Lilly USA, LLC$298
- Johnson & Johnson$177
- AbbVie$156
- AstraZeneca$150
- plus $861 from 16 others
What the payments were for
- Food & beverage$2,290100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $340 |
| Novartis | 13 | $309 |
| Lilly USA, LLC | 13 | $298 |
| Johnson & Johnson | 8 | $177 |
| AbbVie(2 entities) | 9 | $156 |
| AstraZeneca | 9 | $150 |
| GSK | 6 | $132 |
| Astellas Pharma US Inc | 5 | $98 |
| Pfizer | 5 | $97 |
| Amgen | 5 | $94 |
| E.r. Squibb & Sons, L.L.C. | 5 | $74 |
| Biogen | 3 | $69 |
| Sunovion Pharmaceuticals Inc. | 3 | $53 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 1 | $35 |
| Corium, LLC | 2 | $33 |
| Lundbeck LLC | 1 | $29 |
| Insmed, Inc. | 1 | $27 |
| Eisai Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Abbott | 1 | $17 |
How this compares
$2,290 in reported general payments places this provider in the 85th percentile of 305 geriatric medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 274 | $198,257 |
| OzempicSemaglutide | 96 | $174,777 |
| MyrbetriqMirabegron | 107 | $80,254 |
| XareltoRivaroxaban | 78 | $74,725 |
| TrulicityDulaglutide | 43 | $59,280 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $53,590 |
| ProliaDenosumab | 27 | $46,912 |
| MounjaroTirzepatide | 32 | $35,252 |
| RybelsusSemaglutide | 21 | $29,742 |
| XifaxanRifaximin | 14 | $28,655 |
| JanuviaSitagliptin Phosphate | 19 | $28,613 |
| FarxigaDapagliflozin Propanediol | 37 | $27,332 |
| EntrestoSacubitril/Valsartan | 27 | $23,750 |
| Repatha SureclickEvolocumab | 11 | $11,221 |
| Daptomycin | 15 | $10,451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $340 | $204,519117 claims |
| PfizerEliquis | $97 | $198,257274 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $298 | $94,53275 claims |
| Astellas Pharma US IncMyrbetriq | $98 | $80,254107 claims |
| Johnson & JohnsonXarelto | $177 | $74,72578 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $132 | $68,95470 claims |
| AmgenProlia | $94 | $46,91227 claims |
| AstraZenecaFarxiga | $150 | $27,33237 claims |
| NovartisEntresto | $309 | $23,75027 claims |
| AbbVieSynthroid | $156 | $7,63396 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 305 geriatric medicine providers in Florida.
Other geriatric medicine in Saint Petersburg
- Vijaya CherukuriSaint Petersburg$3K
- Malcolm FraserBrooksville$359K
- Andrew ScanameoTallahassee$172K
- Naushira PandyaDavie$145K
- Rosemary LairdViera$64K
- Jonathan AppelbaumMonticello$59K
- John PotomskiMelbourne$31K
- Valeria Baldivieso HurtadoWinter Park$28K
- Kae FerberNaples$18K
- Stuti DangMiami$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.